17 research firms rate Alnylam Pharmaceuticals (ALNY) as "Moderate Buy" with an average 1-year price target of $216.19.
17 research firms covering Alnylam Pharmaceuticals (ALNY) give an average "Moderate Buy" rating, with 7 hold recommendations and 10 buy recommendations. The average 1-year price target among analysts is $216.19. Recent analyst updates include RBC's "outperform" rating and $235.00 target, W. Blair's "outperform" rating, and Citi's price target lowered to $227.00 with a "buy" rating.
June 01, 2024
3 Articles